S. 142 · 118th Congress (2023–2025)
Preserve Access to Affordable Generics and Biosimilars Act
This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.
An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.
When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.
The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.
Show official title
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReported by committee
This bill’s path
This is S. 142’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Amy Klobuchar (D-MN)
- Cosponsors
10 cosponsors
7 original · 3 later
3 R · 7 D
- Sen. Richard Blumenthal (D-CT)· Original · Jan 30, 2023
- Sen. Cory A. Booker (D-NJ)· Original · Jan 30, 2023
- Sen. Kevin Cramer (R-ND)· Original · Jan 30, 2023
- Sen. Richard J. Durbin (D-IL)· Original · Jan 30, 2023
- Sen. Chuck Grassley (R-IA)· Original · Jan 30, 2023
- Sen. Mark Kelly (D-AZ)· Original · Jan 30, 2023
- Sen. Chris Van Hollen (D-MD)· Original · Jan 30, 2023
- Sen. Joni Ernst (R-IA)· Later · Feb 1, 2023
- Sen. Jon Ossoff (D-GA)· Later · Feb 1, 2023
- Sen. Peter Welch (D-VT)· Later · Feb 9, 2023
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Competition and antitrust
- Contracts and agency
- Federal Trade Commission (FTC)
- Intellectual property
- Judicial review and appeals
- Licensing and registrations
3 more
- Manufacturing
- Marketing and advertising
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Jan 30, 2023 – Mar 1, 2023
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Reported by committee → No further action before the 118th Congress ended.
Committees
Feb 9, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Preserve Access to Affordable Generics and Biosimilars Act
Display title, Short title · Introduced in Senate, Reported to Senate
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Official title · Introduced in Senate